Answer
VITRAKVI (larotrectinib sulfate) is contraindicated in patients with hypersensitivity to the active substance or any excipient listed in section 6.1.
Sources for this answer
- Vitrakvi 25 mg hard capsulesBayer plc · emc · SmPC §4.3 Contraindications · Version 14Document updated
Sources checked